PHG — Koninklijke Philips N.V.

Summary of Philips Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Order Intake: Grew by 6%, with comparable sales increasing by 4% across all segments, particularly strong in Personal Health.
• Adjusted EBITDA Margin: Improved by 40 basis points to 9%, marking the sixth consecutive quarter of margin expansion.
• Net Income: Rose to EUR 146 million, with adjusted diluted earnings per share at EUR 0.23, down from EUR 0.25 year-on-year due to currency effects and a higher share count.
• Free Cash Flow: Inflow of EUR 28 million, a EUR 94 million improvement year-on-year when excluding prior year settlement payouts.
• Cash Position: Ended Q1 with EUR 2.6 billion in cash, after a EUR 265 million acquisition payment.

2. Strategic Updates and Business Highlights

• Business Segments:
  • Diagnosis & Treatment (D&T): Comparable sales increased by 2%, driven by high single-digit growth in Image Guided Therapy (IGT) and solid demand for MR systems.
  • Connected Care: Order intake grew in high single digits, with strong demand for monitoring solutions, particularly in North America and Europe.
  • Personal Health: Achieved 9% sales growth, with strong performance in North America and expansion of distribution channels.
• Innovation: Received 20 510(k) clearances, including for AI-powered solutions in MRI and CT. Continued focus on AI integration across products.
• Partnerships: Signed a long-term strategic partnership with WellSpan Health to enhance imaging and diagnostic technologies.

3. Forward Guidance and Outlook

• Full Year Guidance: Reiterated expectations for comparable sales growth of 3% to 4.5%, with North America and international regions anticipated to lead.
• Adjusted EBITDA Margin: Guidance remains at 12.5% to 13% for the full year, despite anticipated cost inflation and tariff impacts.
• Free Cash Flow Outlook: Expected to remain unchanged at EUR 1.3 billion to EUR 1.5 billion.

4. Bad News, Challenges, or Points of Concern

• China Market: Continued pressure from centralized procurement affecting sales in ultrasound and CT, leading to lower order conversion and price-focused environments.
• Cost Inflation: Rising input costs, particularly in freight and electronic components, are expected to impact margins. The company is actively implementing mitigation strategies.
• Geopolitical Risks: Developments in the Middle East may affect sales, although not materially at the group level.

5. Notable Q&A Insights

• D&T Growth: Strong order intake in IGT is driving growth, while China’s centralized procurement is negatively impacting Precision Diagnosis.
• Pricing Strategy: Philips is implementing selective price increases in segments where they hold strong positions, such as IGT and monitoring.
• Competitive Landscape: The company views the recent changes in ownership among competitors in patient monitoring as neutral, maintaining confidence in their market position.
• Long-term Strategy in China: Philips is focusing on differentiated segments like MR and IGT, while deprioritizing more commoditized areas like generic CT and DXR.

Overall, Philips reported a solid start to 2026, with growth across segments and a focus on innovation and strategic partnerships, while navigating challenges in specific markets and cost pressures.